Welcome to PharmaRoth Labs, Inc.
Related Articles:

PharmaRoth Labs Inc. is focused on diabetes prevention and treatments. The Company holds the intellectual property and other exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, a oral treatment for Type II diabetes.

Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.

Unlike pharmaceutical anti-diabetes medications which carry a risk of serious cardiovascular risks and potential liver damage, Sucanon® is an herbal-based nutraceutical treatment for Type-2 diabetes. Growth of the nutraceutical market has been dramatic in the last decade, with nearly two-thirds of the American population taking at least one type of nutraceutical health product. The global nutraceuticals product market is expected to reach $204.8 billion by 2017. Over 30% of diabetes patients in the United States now use "Complimentary and Alternative Medicine", which includes nutraceutical products, to manage their health.

Pharmaroth Labs, Inc.’s securities are traded on the OTC Market under the ticker symbol ROTH.


Type 2 Diabetes in the News

Diabetes numbers rise, CDC says

Zero Healthcare and Top 10 Diabetes World Ranking Make More Trouble for Egypt

Protecting Yourself From the Cost of Type 2 Diabetes

105 Million in U.S. Have Diabetes or Prediabetes, CDC Says

Half of Americans Facing Diabetes by 2020

New Diabetes Figures in China

Diabetes to Double or Triple in U.S. By 2050, CDC Says

4890346 4890347 4890348 4890349 4890350 4890351 4890352 4890353 4890354 4890355 4890356 4890357 4890358 4890359 4890360 4890361 4890362 4890363 4890364 4890365 4890366 4890367 4890368 4890369 4890370 4890371 4890372 4890373 4890374 4890375 4890376 4890377 4890378 4890379

Type 2 Diabetes Resources

International Diabetes Federation

World Diabetes Foundation

American Diabetes Association

World Health Organization

Wikipedia, the free encyclopedia

k s y h b

Insulin Sensitizers and other Type II Diabetic Drugs

Insulin Sensitizers for Type 1 and Type 2 Diabetes
Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes
Review: Insulin Sensitizers
Diabetes Death Watch Slipped Into Health Law by Lilly, Novo

Home  |  Company  |  Diabetes  |  Sucanon  |  Investor Relations  |  Contact  |  Legal Disclaimer  |  Privacy Policy